ArticleSpringerPlus2015

A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22.

Maureen Elizabeth Trudeau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.